---
title: "treatment-of-myelofibrosis"
date: "2024-08-24"
tags:
  - building
---

> [!NOTE]
> üå± created from: [[myelofibrosis]]

# Treatment of myelofibrosis

READ:

## How I treat transplant-eligible patients with myelofibrosis

> Kr√∂ger N, Wolschke C, Gagelmann N. How I treat transplant-eligible patients with myelofibrosis. Blood. 2023;142(20):1683-1696. doi:10.1182/blood.2023021218

<img alt="h:450px" width="1160" src="https://i.imgur.com/vYGV3dX.png" />

## The management of myelofibrosis: A British Society for Haematology Guideline

> McLornan DP, Psaila B, Ewing J, et al. The management of myelofibrosis: A British Society for Haematology Guideline. British Journal of Haematology. 204(1):136-150. doi:10.1111/bjh.19186

## JAK inhibitors

- [[comfort-i.md|COMFORT-I]]

  - How to adjust dose for ruxolitinib
  - Monitor for skin cancer, TB, herpes

- [[fedratinib.md|fedratinib]]

- Transplant? [[mtss.md|MTSS]] when Ruxolitinib got the best response in the first place, around 3 months after the start of treatment
- [[rr6.md|RR6]] for response to ruxolitinib
- second line:
  - [[momentum.md|Momentum]] Simplify-1, Simplify-2
  - PERSIS-2 for thrombocytopenia

Novel [[bet_inhibitor.md|BET Inhibitor]] for Advanced Myelofibrosis
[[independence.md|INDEPENDENCE]]
[[imbark.md|IMBark]]

## TLDR

- High risk patients, consider HSCT in the first place or clinical trials
- low risk patients, consider Ruxolitinib,
  - handle anemia, thrombocytopenia
  - failure, then consider 2nd line JAKi
